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ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) strains cause serious nosocomial infections all over
the world. Overall, approximately 20% of S. aureus isolates in Europe are reported as methicillin-
resistant, whereas in US hospitals the prevalence ranges from 33% to 55%. The past few years have also
witnessed an increase in life-threatening community-acquired infections caused by Panton–Valentine
leukocidin-producing MRSA in the USA. Increasing use of glycopeptides for treatment of community-
acquired MRSA infections may result in higher rates of glycopeptide resistance. Since 1996, five
vancomycin-intermediate S. aureus (VISA; vancomycin MIC = 8–16 mg ⁄L) strains have been identified
in Europe, Asia and the USA, and vancomycin-resistant S. aureus (VRSA) strains (vancomycin
MIC ‡ 32 mg ⁄L) have also been reported in the USA between 2002 and 2005. Most infections with VISA
and VRSA have occurred in a setting of heavy prior use of glycopeptides and other antimicrobial agents.
Emergence of reduced vancomycin susceptibility in S. aureus increases the possibility that currently
available antimicrobial agents may become ineffective for treating systemic infections, especially
bacteraemia, endocarditis and osteomyelitis. Ceftobiprole is a novel broad-spectrum cephalosporin with
expanded activity against Gram-positive bacteria, including MRSA. Ceftobiprole is refractory to the
development of endogenous resistance both in vitro and in vivo. The additional activity of ceftobiprole
against MRSA strains makes it a potentially important addition to currently available agents.
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INTRODUCTION
Staphylococcus aureus is a major cause of serious
hospital-acquired infections. In the past decade,
the prevalence of methicillin-resistant S. aureus
(MRSA) strains has increased worldwide and
they now represent a serious cause of nosocomial
infections in many countries [1]. In Europe,
approximately 20% of S. aureus isolates are repor-
ted as methicillin-resistant, and in the USA, the
prevalence of MRSA is > 50% [2]. The past few
years have also witnessed an increase in life-
threatening community-acquired infections
caused by Panton–Valentine leukocidin (PVL)-
producing MRSA in the USA. Recent data have
shown important changes in the pattern of anti-
biotic resistance among MRSA isolates over time
[1]. Since 1996, vancomycin-intermediate S. aureus
(VISA) isolates, with an MIC for vancomycin of 8–
16 mg ⁄L, have been identified in Europe, Asia,
and the USA [3]. Since 2002, vancomycin-resistant
S. aureus (VRSA) (vancomycin MIC ‡ 32 mg ⁄L)
has been reported in the USA (J. T. Rudrick,
personal communication) [4,5]. There is now a
fifth report, also from Michigan (D. M. Sievert,
personal communication). Infections attributed to
VISA and VRSA often occur after repeated use of
other antimicrobial agents.
Currently, all available b-lactams are consid-
ered to be inactive against MRSA strains.
Increased resistance to antimicrobial drugs is not
confined to staphylococci but also has been
reported with other Gram-positive and Gram-
negative pathogens [6]. Further multidrug-resist-
ant VISA strains have been identified [7], and
VRSA strains are also multiresistant. The emer-
gence of VISA and VRSA suggests that currently
available antimicrobial agents may become inef-
fective in the future for treating systemic infec-
tions such as bacteraemia, endocarditis, and
osteomyelitis. This article will discuss challenges
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posed by the rising incidence of MRSA, VISA, and
VRSA, and address the question: ‘Can b-lactams
act against MRSA?’
EPIDEMIOLOGY OF MRSA
The European Antimicrobial Resistance Surveil-
lance System is an ongoing surveillance pro-
gramme for documenting antimicrobial
resistance. The prevalence of MRSA and changes
in the prevalence over time in European Antimi-
crobial Resistance Surveillance System-participa-
ting countries are routinely collected and
recorded [1]. Between January 1999 and Decem-
ber 2002, 50 759 nosocomial isolates were collec-
ted from 495 hospitals in 26 countries. The
prevalence of MRSA varied from < 1% in north-
ern Europe to > 40% in southern and western
Europe. During this time, the incidence of MRSA
increased significantly in many countries, includ-
ing Belgium, Germany, Ireland, and the UK (Fig.
1), highlighting the need for better infection
control procedures.
In the USA and in Asian countries (including
Taiwan, Korea, and Australia), the incidence of
MRSA isolates is also increasing dramatically
[6,8–10]. Hsueh et al. reported an increase in the
prevalence of MRSA isolates from 26% to 77%
between 1986 and 2001 in Taiwan [10]. During the
period 1999–2001, the prevalence of MRSA was
64% in Korean tertiary-care hospitals [8]. Thus,
MRSA is increasingly a problem worldwide.
COMMUNITY-ACQUIRED MRSA
MRSA has historically been considered to be a
problem associated with the hospital environ-
ment. However, in recent years a dramatic
increase in the prevalence of MRSA has been
reported that is linked to an expanding reservoir
of community-acquired MRSA (CA-MRSA) [11].
The first CA-MRSA isolate was noted among
intravenous drug users in Detroit, Michigan [12].
Other populations in the USA in which CA-MRSA
has been found include: children without identi-
fied risks; the disadvantaged; native American
Indians in Alaska, Minnesota, and Washington;
prison populations; and the urban homeless [13].
In the early 1990s, CA-MRSA was reported among
aboriginal populations or native islanders living
in Australia and New Zealand [13]. Recently,
reports of CA-MRSA include athletes participa-
ting in contact sports [14,15] and those infected
with human immunodeficiency virus [16]. Life-
threatening pneumonia [17] and infections in the
neonatal unit [18] involving MRSA have also been
described. The rates of colonisation or infection
with CA-MRSA are difficult to determine. Hidron
et al. reported nasal colonisation with CA-MRSA
in 7% of their population, which was higher than
the 1–5% reported in other studies [16]. A recently
published review reported similar levels in a
variety of settings, including community-based
high-risk populations [19].
A number of risk-factors for CA-MRSA have
been identified. In many cases, patients have
received antibiotic therapy within the previous
3 months, have been hospitalised within the
previous 12 months, are residents in long-term
care facilities, or have a history of chronic illness
[16,20]. Looking at the secular trend of MRSA in
San Francisco, a marked increase in the total
number of MRSA isolates was observed between
1996 and 2002 [11]. This increase can be attributed
to the increase in the number of CA-MRSA
isolates, with residents in long-term care facilities
and day care centres acting as a reservoir for these
organisms [21].
The molecular biology of hospital-acquired
MRSA (HA-MRSA) is distinct from that of
CA-MRSA. HA-MRSA isolates usually contain
the type I, II or III genetic element staphylococcal
Fig. 1. Percentage of Staphylococcus aureus isolates that
were methicillin-resistant by country from 1999 to 2002 in
Europe [1]. MRSA, methicillin-resistant S. aureus.
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cassette chromosome mec (SCCmec), which con-
fers resistance to currently available b-lactam
antibiotics and also many other non-b-lactam
antibiotics [22]. HA-MRSA exhibits multidrug
resistance to drugs such as clindamycin, gentam-
icin, and fluoroquinolones. By contrast,
CA-MRSA isolates often possess a novel type IV
SCCmec, as well as the PVL gene, which encodes
for a toxin contributing to the virulence of
infection [19,22]. Thus, MRSA represents a grow-
ing problem worldwide, and therapeutic options
for these infections remain untested.
DECREASING VANCOMYCIN
SENSITIVITY OF S . AUREUS
The emergence of VISA and VRSA has also
compromised treatment options for Gram-posit-
ive infections. The first reported case of decreased
sensitivity of S. aureus to vancomycin was des-
cribed in 1996 [23]. The mechanism for resistance
or decreased sensitivity of S. aureus to vancomy-
cin and glycopeptides in general is thought to be
due to cell wall alterations, which result in
thickening of the bacterial cell wall [24] and cell
wall reorganisation [25]. In addition, overproduc-
tion of penicillin-binding protein (PBP2) has been
observed [26], and absent PBP4 expression has
also been reported [27]. Resistance to vancomycin
is mediated by the vanA gene, which is specific for
glycopeptides. Other genes found in VRSA strains
include mecA for b-lactams, erm(A) and erm(B) for
macrolides, aac-aph for aminoglycosides, and tetK
for tetracyclines. Mutations of GyrA S84L and
GrlB E471K are associated with resistance to
quinolones [5,28,29].
VISA
VISA was first identified in isolates from two
patients in 1996 [23]. The first VISA strain was
isolated from a leg ulcer and a catheter tip of a
patient who had responded poorly to vancomycin
treatment. The second VISA strain was isolated
from an infant who also responded poorly to
vancomycin treatment. Subsequently, a case of
VISA was reported from a hospital in France [30],
and since then other cases of infections due to
VISA have been reported in the USA and else-
where [7,31,32]. Patients at increased risk for
VISA include those having recurrent MRSA
infections treated with vancomycin and those
with chronic renal failure [31]. Additional strains
of MRSA exhibiting reduced susceptibility to
vancomycin have also been reported in France
[33,34]. In total, there have been about 100
staphylococcal isolates with reduced susceptibil-
ity to vancomycin (VISA) reported in Europe,
Asia, and the USA.
VISA strains cannot be detected reliably by
standard disk diffusion methods [7,31,32]. The
current Clinical and Laboratory Standards Insti-
tute guidelines define VISA as having a vanco-
mycin MIC of 8–16 mg ⁄L; however, in cases
where other susceptibility testing methods have
been used, vancomycin MICs of 4–8 mg ⁄L have
been found [7,32]. Also, reports have appeared of
patients with endocarditis caused by S. aureus
strains with vancomycin MICs of 4 mg ⁄L, which
have not responded to vancomycin [35–37].
S. aureus isolates for which vancomycin MICs
are ‡ 4 mg ⁄L should be sent to a public health
laboratory for confirmation [31], because automa-
ted methods for detecting VISA are not accept-
able. Acceptable methodology for detecting VISA
includes Clinical and Laboratory Standards Insti-
tute broth microdilution, agar dilution, and Etest,
although the exact MIC for defining resistance is
not clear. The CDC recommends an MIC of
8–16 mg ⁄L using broth microdilution, growth of
> 1 colony in 24 h using agar dilution, and an MIC
‡ 6 mg ⁄L using the Etest method. Additional
research is required to fully delineate optimal
laboratory testing for these resistant isolates.
VISA strains may, depending on the site of
infection, remain susceptible to treatment with
vancomycin, but often require higher doses and
prolonged treatment periods, and most are sus-
ceptible to trimethoprim–sulphamethoxazole [31].
Clinically, serious infections may occur with
S. aureus strains exhibiting vancomycin MICs of
4 and even 2 mg ⁄L, which do not respond to
vancomycin [31].
The above reports, together with documented
cases of resistance to teicoplanin, especially
among coagulase-negative staphylococci, indicate
the growing problem of resistance among staphy-
lococci to all classes of antimicrobial agents,
including glycopeptides.
VRSA
In early 2002, the first VRSA strain containing a
vanA-resistant gene was isolated in Detroit [4].
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About 6 months later, a second VRSA strain was
isolated from an obese elderly man in Hershey,
Pennsylvania [5], and early in 2004 a third strain
of VRSA was isolated from a urine specimen from
a patient in a long-term care facility [38]. In early
2005, a fourth VRSA strain was isolated from a toe
wound of an elderly patient who had recently
been hospitalised for aortic valve replacement
and then spent 5 weeks in a nursing home (J. T.
Rudrick, personal communication).
These four cases all occurred in elderly, debi-
litated patients with one or more chronic diseases,
such as diabetes mellitus, chronic renal failure, or
peripheral vascular disease. Obesity and ⁄ or resi-
dence in a long-term care facility, as applies to
three of these patients, may also be risk-factors for
development of resistance. Patients with VISA or
VRSA have usually been treated with multiple
previous courses of antibiotic therapy, which may
predispose patients to complicated, multidrug-
resistant infections. In addition, Fridkin et al.
determined that recent vancomycin use and a
positive culture for MRSA within the previous 2–
3 months were risk-factors for reduced suscepti-
bility to vancomycin [28].
Different characteristics of the first three strains
of VRSA are noted in Table 1. In the Michigan
case, the vancomycin MIC was 1024 mg ⁄L,
whereas the other two strains had much lower
MICs (32–64 mg ⁄L), despite all three strains
containing the vanA gene. However, the patient
in Michigan had also received previous vanco-
mycin therapy, and vancomycin-resistant Entero-
coccus faecalis had been isolated from the same
wound in which the VRSA was initially cultured.
The difference between the MICs of the Pennsyl-
vania and New York strains and the first Mich-
igan case could be attributed to the level of
expression of the vanA gene present on the 120-kb
plasmid, which was present in the Pennsylvania
and New York strains but not in the Detroit strain,
and is not typical of S. aureus. This 120-kb
plasmid may represent either an enterococcal or
co-integrated plasmid composed of enterococcal
and staphylococcal plasmid sequences. For both
the first Michigan VRSA strain and the NYC
VRSA strain, potential vancomycin-resistant en-
terococcal donors were found in the same patient
(F. Tenover, personal communication). All of the
first three VRSA isolates remained sensitive to
multiple other antibiotics on in-vitro testing,
including imipenem, linezolid, minocycline, qui-
nupristin–dalfopristin, rifampin, and trimetho-
prim–sulphamethoxazole. From the preliminary
report (J. T. Rudrik, personal communication), it
appears that a vancomycin-resistant E. faecalis
strain was grown from a rectal culture of the
patient. More information on this fourth VRSA
strain is not currently available. In summary, the
only patient with a VRSA strain but no vanco-
mycin-resistant enterococci was from Hershey [5].
As with VISA, automated susceptibility testing
methods have failed to reliably detect VRSA
strains. Thus, it has been recommended that a
non-automated method of susceptibility testing,
such as a vancomycin-agar screening plate or
conventional agar, microdilution MIC or Etest be
used when S. aureus is isolated [5,38].
RISING GRAM-POSITIVE
RESISTANCE AND THERAPEUTIC
OPTIONS
Unfortunately, the consequence of increasing
resistance among S. aureus and other pathogens
is an increase in morbidity and mortality due to
bacteraemia [29,39]. Outcomes of S. aureus infec-
tions in critically ill patients with bacteraemia
were assessed in a retrospective analysis [39].
Compared to patients with methicillin-sensitive
S. aureus (MSSA), patients with MRSA bacterae-
mia experienced more acute renal failure and
haemodynamic instability, had longer stays in the
intensive care unit, and were more dependent on
a ventilator. In-hospital and 30-day mortality
were significantly (p < 0.05) higher among MRSA
patients than among MSSA patients, even after
adjustment for disease severity.
In a prospective evaluation of patients with
S. aureus bacteraemia [29], patients with MRSA
were significantly more likely to develop compli-
cations including endocarditis and bacteraemia
than those with MSSA (Fig. 2). Adverse outcomes
were significantly greater in patients with MRSA
Table 1. Comparison of features from the first three VRSA
isolates [4,5,38]
VRS1
Michigan
VRS2
Pennsylvania
VRS3
New York
MIC 1024 mg ⁄L 32 mg ⁄L 64 mg ⁄L
Vancomycin treatment Yes No ?
VRE Yes No Yes
Plasmid 60 kb 120 kb 120 kb
In-vitro transfer No No ?
Carrier No No ?
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infections. Similarly, in a surveillance programme
conducted at 274 sites in Germany to examine
differences in mortality and risk-factors associated
with nosocomial S. aureus infections in intensive
care unit patients [40], MRSA was associated with
a significantly higher mortality rate.
A retrospective analysis of MRSA bacteraemia
in a neonatal intensive care unit [18] reported
8 ⁄ 17 (47%) to be due to MRSA. Isolates from six
of the eight infants with MRSA carried the
SCCmec type IV genes, a feature of CA-MRSA in
the USA. All six isolates were resistant to macro-
lides and b-lactams, and one was also resistant to
clindamycin. One non-typeable isolate carried the
SCCmec type II gene characteristically found in
HA-MRSA, and was only susceptible to vanco-
mycin. Seven (88%) infants developed septic
shock, three infants died, and three survivors
required prolonged antibiotic therapy for compli-
cations.
NEED FOR NEW b -LACTAMS
There are now limited therapeutic options for
treating serious bacterial infections, and in the
face of increasing resistance, an urgent need exists
for new antibiotics. Vancomycin is becoming less
than optimal for treating MRSA and other resist-
ant Gram-positive bacteria. Widespread use of
vancomycin (which is already widely used orally
in the treatment of pseudomembranous colitis) in
the community to treat CA-MRSA infection cau-
ses an increased selective pressure that is ideal for
selection of VISA and maintenance of vanA
plasmids in S. aureus strains. Resistance to linezo-
lid is emerging rapidly [41], and it can be
expected that resistance to other antibiotics used
for treating MRSA will increase over time. All
currently available b-lactam antibiotics are inac-
tive against resistant staphylococci. New antimi-
crobial agents that overcome current resistance
mechanisms are needed to treat MRSA and other
resistant bacteria. Restoring the trusted activity of
cephalosporins to include MecA-triggered resist-
ance would be a great achievement in antimicro-
bial development.
CEFTOBIPROLE
Ceftobiprole is the first of a new class of paren-
teral cephalosporins, and is highly b-lactamase-
stable. Ceftobiprole has demonstrated a strong
affinity for penicillin-binding proteins (PBP2,
PBP2x, PBP1a) present in a wide variety of
bacteria, including staphylococci, pneumococci,
and other Gram-positive and Gram-negative
pathogens, and especially for PBP2a, which medi-
ates resistance of MRSA to b-lactams. Ceftobipro-
le medocaril, a water-soluble prodrug, is rapidly
converted in human plasma to the active drug,
ceftobiprole. Results from single- and multiple-
dose pharmacokinetic studies demonstrate that
the mean volume of distribution for ceftobiprole
(16–20 L) approximates the extracellular compart-
ment, suggesting extensive extracellular distribu-
tion [42,43]. Ceftobiprole is eliminated primarily
by renal excretion with a half-life of 3–4 h.
The in-vitro antibacterial activity of ceftobiprole
and other antimicrobial agents was compared
against staphylococcal isolates (Ednie L, Appel-
baum PC. Antistaphylococcal activity of ceftobi-
prole [BAL9141] and comparators. 44th ICAAC
2004, abstract E-2021). Bacteria included 152 MSSA
Fig. 2. The effects of increasing resistance among Staphy-
lococcus aureus isolates on mortality [29,39]. MRSA,
methicillin-resistant S. aureus; MSSA, methicillin-suscept-
ible S. aureus.
Table 2. Comparative activities (MIC90) of various anti-
microbial agents against methicillin-sensitive and -resist-
ant Staphylococcus aureus and coagulase-negative
staphylococci (CNS) [44]
Staphylococcus aureus CNS
Meth-R Meth-S Meth-R Meth-S
Ceftobiprole 2 0.5 2 1
Cefazolin > 32 1 32 1
Linezolid 2 2 2 2
Quinupristin–dalfopristin 0.5 0.5 0.5 0.25
Minocycline 2 0.12 0.5 0.25
Gentamicin > 16 > 16 > 16 0.25
Co-trimoxazole > 8 8 > 8 8
Vancomycin 1 1 2 2
Teicoplanin 2 1 16 4
Daptomycin 0.5 0.5 0.5 0.5
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and MRSA strains and 151 MSSA and MRSA
coagulase-negative strains (Table 2). The MIC90
for ceftobiprole was < 4 mg ⁄L for all isolates, and
100% of isolates were susceptible to ceftobiprole
at a preliminary breakpoint of 4 mg ⁄L (Ednie L,
Applebaum PC. Antistaphylococcal activity of
ceftobiprole [BAL9141] and comparators. 44th
ICAAC 2004, abstract E-2021). Ceftobiprole MICs
were in the range of 0.5–2 mg ⁄L for VISA, VRSA,
and coagulase-negative isolates. All strains were
also susceptible to linezolid, quinupristin–dal-
fopristin, daptomycin, and vancomycin, but
resistant to amoxycillin–clavulanate, cefazolin,
gentamicin, levofloxacin, and teicoplanin.
Time-kill studies comparing the activity of
ceftobiprole with the activities of 18 other antimi-
crobial agents against drug-resistant staphylococ-
cal isolates found that at concentrations twice the
MIC, ceftobiprole was bactericidal for 11 of 12
isolates (Fig. 3) (Lin G, Appelbaum PC. Compara-
tive time-kill determination of the antipneumo-
coccal activity of ceftobiprole [BAL9141]. 14th
ECCMID 2004, abstract E-2019). Other compara-
tors also demonstrated bactericidal activity by
24 h, but linezolid was bacteriostatic.
The potential for development of endogenous
resistance in three methicillin-resistant staphylo-
coccal isolates was examined for ceftobiprole,
linezolid, and moxifloxacin (Heller S, Marrer E,
Page MGP, Shapiro S, Thenoz L. Development of
endogenous resistance by staphylococci to
BAL9141 and comparators. 14th ECCMID 2004,
abstract P675). Each isolate was serially trans-
ferred at 48-h intervals on Mueller–Hinton agar
containing either ceftobiprole, linezolid or mox-
ifloxacin until the MIC exceeded 64 mg ⁄L, up to a
maximum of 50 passages. The MIC of ceftobiprole
reached a plateau of 32 mg ⁄L after 50 passages,
whereas the MIC exceeded 64 mg ⁄L with linezo-
lid after 27–28 passages and with moxifloxacin
after 4, 8 or 22 passages, depending upon the
strain (Fig. 4). Another serial passage study, this
one performed at 24-h intervals in liquid medium,
yielded MICs of ceftobiprole in the 1–8 mg ⁄L
range by 50 passages. In comparison, the MIC of
linezolid reached 64 mg ⁄L in some clones and
increased from 8 to 16 mg ⁄L in others [44]. These
results strongly suggest that emergence of resist-
ance during treatment with ceftobiprole is highly
unlikely. Similar experiments conducted first by
Hebeisen et al. showed that the ceftobiprole
MIC90 for MRSA was 4 mg ⁄L. Ceftobiprole was
bactericidal against MRSA, and the development
of resistance in MRSA was not observed [45].
Favourable results from a phase II trial in
patients with complicated skin and skin structure
infections have been reported (Heep M, Querner
S, Harsch M, O’Riordan W. Ceftobiprole
[BAL5788], the first of a new class of anti-MRSA
cephalosporins: microbiological results from a
phase II study in complicated skin and skin
structure infections. 44th ICAAC 2004, abstract
L-361). Phase III clinical trials have been initiated
with ceftobiprole for the treatment of complicated
skin and skin structure infections and hospital-
acquired pneumonia.
CONCLUSIONS
Changing patterns of resistance have compoun-
ded and exacerbated the need for new antimicro-
bial agents. Ceftobiprole is a promising new
cephalosporin that is refractory to the develop-
ment of endogenous resistance in staphylococci.
Not only is ceftobiprole active against MRSA and
other Gram-positive organisms, but it also dem-
onstrates activity comparable to that of cefepime
against Enterobacteriaceae and Pseudomonas spe-
Fig. 3. Ceftobiprole time-kill graph of vancomycin-resist-
ant Staphylococcus aureus strain [45].
Fig. 4. Development of endogenous resistance by a meth-
icillin-resistant Staphylococcus aureus clinical isolate (Heller
S, Marrer E, Page MGP, Shapiro S, Thenoz L. Development
of endogenous resistance by staphylococci to BAL9141 and
comparators. 14th ECCMID 2004, abstract P675).
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cies (Kresken M, Heep M. In vitro activities of
BAL9141, the active component of BAL5788, and
seven other beta-lactams against selected strains
of Pseudomonas aeruginosa susceptible or resis-
tant to ceftazidime. 14th ECCMID 2004, abstract
E-2022. Jones RN, Sader HS, Fritsche TR. In vitro
susceptibility testing guidelines for ceftobiprole
[BAL9141] using CLSI disk diffusion and broth
microdilution MIC methods. 45th ICAAC 2005,
abstract D-1647) and is active and bactericidal
against Haemophilus influenzae and Moraxella
catarrhalis (Appelbaum PC, Smith K. MIC values
of ceftobiprole and comparators towards Haemo-
philus influenzae and Moraxella catarrhalis. 45th
ICAAC 2005, abstract E-304. Pankuch G, Lin G,
Appelbaum PC. Time-kill activities of ceftobiprole
and eight other agents against H. influenzae and
M. catarrhalis. 45th ICAAC 2005, abstract E-305.
Clark C, Bogdanovich T, Ednie LM, Appelbaum
PC. Low propensity of ceftobiprole to select for
resistant mutants of H. influenzae and M. catar-
rhalis. 45th ICAAC 2005, abstract E-316). Ceftobi-
prole is expected to be an important addition to
the antimicrobial armamentarium for treating
serious infections, particularly those associated
with resistant organisms.
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